Detlef Albrecht - 03 Jun 2022 Form 4 Insider Report for Satsuma Pharmaceuticals, Inc.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 03 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jun 2022, 17:39:34 UTC
Source filing: View source filing
Reporting owner signature: /s/ Thomas P. O'Neil as Attorney in Fact for Detlef Albrecht, M.D.

Key filing fact

Detlef Albrecht filed Form 4 for Satsuma Pharmaceuticals, Inc. on 07 Jun 2022.

Key facts

This page summarizes Detlef Albrecht's Form 4 filing for Satsuma Pharmaceuticals, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Jun 2022, 17:39.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STSA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +190,000
Change %
Price: $0.000000
Shares after: 190,000
Date: 03 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 190,000
Exercise price: $3.46
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Twenty Five Percent (25%) of the shares subject to the option vest one year measured from June 3, 2022 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.